前列腺癌进展和耐药性的新特征

IF 4.6 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert Opinion on Therapeutic Targets Pub Date : 2023-12-18 DOI:10.1080/14728222.2023.2293757

Jason Wang, Reuben Ben-David, Reza Mehrazin, Wei Yang, Ashutosh K. Tewari, Natasha Kyprianou

引用次数: 0

摘要

前列腺癌（PCa）具有广泛的异质性，而且进展为去势抵抗性前列腺癌（CRPC）的过程具有多层次的复杂性，这些都给准确监测前列腺癌的进展带来了挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Novel signatures of prostate cancer progression and therapeutic resistance

The extensive heterogeneity of prostate cancer (PCa) and multilayered complexity of progression to castration-resistant prostate cancer (CRPC) has contributed to the challenges of accurately monito...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Opinion on Therapeutic Targets 医学-药学

CiteScore

8.90

自引率

1.70%

发文量

审稿时长

3 months

期刊介绍： The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials. The Editors welcome: Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development. Articles should not include clinical information including specific drugs and clinical trials. Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.